In a significant regulatory move, the Food Safety and Standards Authority of India (FSSAI) has banned the use of ashwagandha leaves in food products, allowing only the root of the herb to be used. The advisory issued on April 16 directs all food business operators to comply with the updated guidelines or face action under the Food Safety and Standards Act, 2006.
The move is based on the recommendation of the Ministry of Ayush, which noted that traditional Ayurvedic practices largely use ashwagandha root for its therapeutic benefits. Manufacturers are currently obligated to properly label the plant parts used, further enhancing the transparency to consumers.
Leaves Prohibited?
The limit on Ashwagandha is mainly based on the new safety issues. A 2024 safety dossier submitted by Indian officials indicates that ashwagandha leaves have a higher concentration of compounds called withanolides, specifically withaferin A. Such compounds are biologically active, but when ingested in large quantities, they might be hazardous.
Possible problems have also been identified in other studies, such as liver toxicity, hormonal disruptions, and effects on the immune system, particularly in the case of products in which leaf extracts or unspecified parts of the plant were used. Conversely, the root possesses a well-established safety profile with clinical trials and conventional use.
What Does This Imply For Your Health?
Ashwagandha is a widely used adaptogen, which is known to help the body cope with stress, sleep better and generally feel better. Researchers observe that such advantages are mainly associated with root-based extracts, which have undergone extensive research on safety and efficacy.
The ban also seeks to minimise the risk of adverse effects associated with the use of inconsistent formulations, especially in the case of supplements which may have used cheaper leaf material without due disclosure. Regulators want to guarantee improved quality control and consumer safety through the standardisation of the use of root-only extracts.
Ban Implications on the Industry
Although some manufacturers have celebrated the move as a step towards harmonising with traditional practices, others believe that the evidence against the use of leaf is inconclusive. Some research indicates that root and leaf extracts are safe when duly standardised, and critics believe that imposing limits on certain compounds might have been a more middle ground than a ban.
Global implications
The Indian market controls the world ashwagandha market; this decision may affect international standards. The relocation is also against the background of the growing questioning of the herb in Europe, where worries about the possibility of side effects have led to restrictions in some countries.
Takeaway
The ban on ashwagandha leaves in India is a step towards more stringent safety and quality guidelines in herbal supplements. It provides consumers with the assurance that selecting products which are made of clinically studied root extracts is important to ensure the effectiveness and safety of using them in the long term.
The Food Safety and Standards Authority of India (FSSAI), in alignment with directives from the Ministry of Ayush, issued a strict advisory prohibiting the use of Ashwagandha (Withania somnifera) leaves—in crude, extract, or any other form—in health supplements, nutraceuticals, and food products.
Here is what this means for product safety, the supplement industry, and consumer health.
1. The Reason Behind the Directive: Safety Concerns
While Ashwagandha root is considered safe and has been used in traditional Ayurvedic practice for millennia, scientific evaluations have highlighted concerns regarding the leaves:
Higher Concentrations of Withaferin-A: Ashwagandha leaves contain significantly higher levels of reactive withanolides, particularly Withaferin-A, compared to the root.
Potential Toxicity Risks: The Ministry of Ayush and FSSAI noted that these higher concentrations are linked to potential safety risks, including liver toxicity (hepatotoxicity), gastrointestinal distress, and potential neurotoxic effects.
Lack of Long-Term Safety Data: While root extracts are well-studied and validated for long-term use, the phytochemical profile of the leaf extract is less understood, prompting regulators to take a precautionary approach.
2. What This Means for Consumers
Root-Based Products Remain Safe and Legal: The restriction applies strictly to the leaves.
The use of Ashwagandha root and its extracts remains completely permitted, safe, and aligned with traditional practices. Increased Transparency: As part of the directive, the FSSAI has instructed manufacturers to clearly state the specific plant parts used on product labels.
Actionable Step for Buyers: If you take Ashwagandha supplements, simply check the ingredient list on the packaging:
Look for: Root extract or root powder.
Avoid / Verify: Products listing "leaf extract," or products that do not clearly specify the plant part used.
3. Industry Impact
Manufacturers and brands are now required to ensure that their formulations exclusively use the root of the plant.
Disclaimer: This information is for educational purposes and does not substitute for professional medical advice. Always consult a healthcare practitioner before making changes to your supplement routine.
No comments:
Post a Comment